Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
16.35
+0.21 (1.30%)
At close: Jun 12, 2026, 4:00 PM EDT
16.34
-0.01 (-0.06%)
After-hours: Jun 12, 2026, 7:41 PM EDT
Viridian Therapeutics Revenue
Viridian Therapeutics had revenue of $141.00K in the quarter ending March 31, 2026, with 95.83% growth. This brings the company's revenue in the last twelve months to $70.84M, up 30,701.30% year-over-year. In the year 2025, Viridian Therapeutics had annual revenue of $70.85M with 23,359.93% growth.
Revenue (ttm)
$70.84M
Revenue Growth
+30,701.30%
P/S Ratio
25.46
Revenue / Employee
$281,421
Employees
252
Market Cap
1.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 70.85M | 70.55M | 23,359.93% |
| Dec 31, 2024 | 302.00K | -12.00K | -3.82% |
| Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
| Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
| Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
| Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
| Dec 31, 2019 | 4.46M | -3.93M | -46.80% |
| Dec 31, 2018 | 8.39M | 4.38M | 109.49% |
| Dec 31, 2017 | 4.00M | 526.00K | 15.13% |
| Dec 31, 2016 | 3.48M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lakefront Biotherapeutics NV | 1.20B |
| Iovance Biotherapeutics | 285.61M |
| Nurix Therapeutics | 71.78M |
| Intellia Therapeutics | 66.09M |
| Agios Pharmaceuticals | 66.05M |
| Mesoblast | 65.38M |
| Nanobiotix | 38.27M |
| Stoke Therapeutics | 32.08M |
VRDN News
- 5 days ago - Viridian Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 5 days ago - Viridian Metals Commences 2026 Diamond Drill Program at the Kraken - GlobeNewsWire
- 9 days ago - Viridian Metals Highlights Copper-Rich Zones up to 4.15% Cu at Kraken Ahead of 2026 Drill Program - GlobeNewsWire
- 11 days ago - Viridian Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 13 days ago - Viridian Therapeutics Slides: Corporate presentation - Filings
- 18 days ago - Viridian Therapeutics to Participate in Upcoming June Investor Conferences - Business Wire
- 26 days ago - Viridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel Project - GlobeNewsWire
- 4 weeks ago - Viridian Therapeutics price target lowered to $26 from $27 at Evercore ISI - TheFly